1stOncology™: Cancer Intelligence Service – Page 12870 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Caris Life Sciences to Present at 31st Annual Piper Jaffray Healthcare Conference

On November 20, 2019 Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, reported that Brian J. Brille, Vice Chairman of the Company, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 12:50 p.m. Eastern Time at Lotte New York Palace Hotel, Kennedy 1 Room, in New York City (Press release, Caris Life Sciences, NOV 20, 2019, View Source [SID1234551552]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Mr. Brille will present a corporate overview and discuss recent expansion and development progress that positions the Company to further extend its leadership in precision medicine. He will also take questions from the audience following the presentation.

Investors attending the conference who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Piper Jaffray representative.

Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer

On November 20, 2019 Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough therapies for patients, reported Kymera Co-founder, President and Chief Scientific Officer Nello Mainolfi, PhD, has been promoted to President and Chief Executive Officer effective immediately (Press release, Kymera Therapeutics, NOV 20, 2019, View Source [SID1234551551]). Mainolfi will lead Kymera as the company enters its next stage of growth, advancing a series of novel degrader drugs into clinical development as well as expanding the impact of its innovative Pegasus platform.

"On behalf of entire Board of Directors, I’m excited to recognize Nello Mainolfi as the next CEO of Kymera Therapeutics, especially at a time of exceptional growth, promising data delivery, and premier partnerships," said Bruce Booth, DPhil, Chairman of the Kymera Board of Directors and partner at Atlas Venture. "Since the inception of Kymera, Nello has demonstrated exemplary leadership and capabilities, and provided strategic direction to advance the development of our powerful new drug discovery engine from target identification into development. With a pipeline of drug candidates advancing into the clinic, we have full confidence that Nello is the best person to successfully position the company and realize the potential of this modality."

Mainolfi started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify novel potential medicines that have entered clinical development across a series of disease areas. Before co-founding Kymera with Booth in 2016, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics.

"I would like to thank the Board of Directors and the entire Kymera team for this unique opportunity," said Mainolfi. "I’ve had the privilege of contributing to the scientific and corporate evolution of Kymera and I look forward to continuing to foster its research & development progress and ambition. I’m excited to help Kymera deliver on our mission of inventing a new class of protein degrader medicines for patients."

ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

On November 20, 2019 ViewRay, Inc. (NASDAQ: VRAY) reported that the Company will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference in New York, New York. Scott Drake, President and CEO, will give a presentation at 1:30p.m. Eastern Time on Wednesday, December 4, 2019 (Press release, ViewRay, NOV 20, 2019, View Source [SID1234551549]).

An audio webcast of the Company’s presentation will be available on the investor relations section of ViewRay’s website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.

CNS Pharmaceuticals Announces Attendance at the 24th Annual Meeting of the Society of Neuro-Oncology

On November 20, 2019 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, reported Chief Executive Officer of CNS Pharmaceuticals, John M. Climaco, along with founder, Waldemar Priebe, PhD, and members of management, including, Chief Medical Officer, Sandra Silberman, MD, PhD, Chief Scientific Officer, Donald Picker, PhD, and scientific advisory board member, Sigmund Hsu, MD, PhD, will be attending the 24th Annual Meeting of the Society of Neuro-Oncology ("SNO") (Press release, CNS Pharmaceuticals, NOV 20, 2019, View Source [SID1234551548]). The event will take place November 20-24, 2019 at the JW Marriott Desert Ridge Resort in Phoenix, Arizona.

"Following our recent IPO, we are looking forward to connecting with the scientific community at the world’s largest neuro-oncology conference," stated John Climaco. "We remain committed to further pursuing the advancement of our novel anthracycline, Berubicin, and to developing therapies for the treatment of glioblastoma."

About Berubicin
Berubicin is an anthracycline, a class of drugs among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to damage the DNA of targeted cancer cells by interfering with the action of the topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), the world’s largest cancer research facility. Berubicin appeared to demonstrate one Durable Complete Response in a Phase I human clinical trial conducted by a prior developer.

Q BioMed Announces FDA Approval

On November 20, 2019 BioMed Inc. (OTCQB: QBIO), reported FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG) (Press release, Q BioMed, NOV 20, 2019, View Source [SID1234551547]). ITG is now cleared to manufacture the Company’s FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP.

The long-awaited approval of the facility means that this important oncologic pain drug will soon be available to patients in the US and the rest of the world. Q BioMed is now the only FDA-approved source for this drug in the western world. The Company is activating its planned commercial operations to support marketing, sales, and distribution in the US and, soon, in the rest of the world.

Strontium-89 is an FDA-approved non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer. The product is administered intravenously once every three months as an alternative to opioid analgesics and plays a critical role in the treatment of metastatic bone pain. The product has a long history of providing well-documented and significant pain relief for patients suffering from the excruciating pain associated with primary cancers that have spread to the bone, including breast, prostate, lung and others. This is the ideal time to be launching Strontium-89 given the current concerns with the over-use of opioid drugs. In addition, as more therapies come to market for the treatment of primary cancers, more people are living longer with metastatic disease. It is estimated that approximately two million patients experience debilitating bone pain from metastatic disease. The opportunity to provide significant pain relief to this group is substantial.

QBioMed CEO Denis Corin said, "We have been anticipating this critical regulatory step for a long time, certainly longer than we hoped, but we are thrilled that we can now move forward with certainty. This is the start of a new chapter in the evolution of our company, and we are looking forward to serving the needs of thousands of patients suffering from metastatic bone pain, providing them the chance to minimize their pain and positively impact life with metastatic disease. With millions of potential patients around the world, this is a major market opportunity for our company. In addition, we are investigating and planning expansion trials to provide additional indications for the drug and entry into an even larger therapeutic market."